Results 81 to 90 of about 1,763 (188)

Clear Cell Renal Cell Carcinoma: Rare and Atypical Metastatic Localizations—A Case Series

open access: yesCase Reports in Urology, Volume 2026, Issue 1, 2026.
Introduction Clear cell renal cell carcinoma (ccRCC) is the most prevalent subtype of kidney cancer, characterized by its high degree of vascularity and metastatic potential. Although common metastatic sites include the lungs, lymph nodes, bones, liver, adrenal glands, and brain, rare localizations, such as those observed in the pancreas, gallbladder ...
Roosvelt Tessa Djambong   +7 more
wiley   +1 more source

Supplementary Material for: Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression

open access: yes
Introduction The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized.
Su Y.-Y. (17887331)   +19 more
core   +1 more source

Management of Metastatic Pulmonary Spindle Cell Carcinoma With Upfront Pembrolizumab‐Chemotherapy and Subsequent Ipilimumab–Nivolumab Salvage Therapy: A Case Report

open access: yesCase Reports in Oncological Medicine, Volume 2026, Issue 1, 2026.
Sarcomatoid carcinoma is a heterogeneous and rare subset of non–small cell lung cancers (NSCLCs), comprising pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, pulmonary blastoma, and carcinosarcoma. Pulmonary spindle cell carcinoma accounts for less than 1% of all NSCLC cases.
Raheel Siddiqui   +3 more
wiley   +1 more source

Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy

open access: yes
International audienceContext : Nonsmall Cell Lung Cancer (NSCLC) treatment relies on first-line immunotherapy as single agent or combined with chemotherapy. Oligoprogression may be observed in this setting.
Basse, C.   +13 more
core   +1 more source

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: A multicenter retrospective analysis [PDF]

open access: yes, 2017
Locoregional treatment with radical intent should be considered during therapy with targeted agents in patients with metastatic renal cell carcinoma (mRCC) in order to achieve a complete response, especially in the setting of an oligo-progression in one ...
Maruzzo M   +62 more
core   +1 more source

NSCLC With Synchronous EGFR Mutations in Li Fraumeni Syndrome: A Case Report

open access: yes, 2023
We report a case of a patient with Li Fraumeni Syndrome (LFS) who developed synchronous EGFR exon deletion 19 and EGFR exon 20 insertion NSCLC and characterize the diagnostic and therapeutic challenges in managing her care.
Stephen V. Liu, MD   +1 more
core   +1 more source

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy

open access: yesFrontiers in Oncology, 2019
Introduction: Therapy options for patients with oligoprogressive malignant pleural mesothelioma (MPM) are limited. Stereotactic Body Radiotherapy (SBRT) may be a promising therapeutic option, as it delivers a localized ablative dose of radiation and ...
Christina Schröder   +7 more
doaj   +1 more source

Radiotherapy in Oligometastatic and Oligoprogressive Disease

open access: yesThe Journal of Tepecik Education and Research Hospital, 2023
Mihriban Erdoğan   +7 more
openaire   +1 more source

Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review

open access: yesCritical Reviews in Oncology/Hematology
Consolidative radiation is increasingly regarded as an effective treatment for oligometastatic and oligoprogressive non-small cell lung cancer (NSCLC). This systematic review examines the clinical evidence on the significance of consolidative radiation in improving outcomes in NSCLC, including progression-free survival and overall survival. Innovations
Nazmul Hasan   +3 more
openaire   +2 more sources

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach

open access: yesExploration of Targeted Anti-tumor Therapy
Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advanced non-small cell lung cancer (NSCLC).
Francesca Di Pressa   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy